Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$152.55 USD

152.55
1,896,406

-0.09 (-0.06%)

Updated Nov 13, 2024 12:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Should iShares Russell 1000 Value ETF (IWD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IWD

Sweta Killa headshot

ETFs in Focus on JNJ's Mixed Q4 Earnings Results

by Sweta Killa

The world's biggest healthcare products' maker continued with its long streak of earnings beat and missed revenue estimates.

Should Schwab U.S. LargeCap Value ETF (SCHV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SCHV

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Stock Market News for Jan 25, 2023

by Zacks Equity Research

Wall Street closed mixed on Tuesday as investors digested the latest batch of corporate earnings reports and gauged the state of the economy.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Johnson & Johnson (JNJ) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2022, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge

Mark Vickery headshot

Q4 Earnings Season Heats Up: JNJ, MMM, GE & More

by Mark Vickery

Whether pre-market futures are reacting to results or just doing some profit-taking off recent highs is hard to tell -- the Dow is -150 points at this hour, the S&P 500 is -20 and the Nasdaq -85 points currently.

J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat

by Zacks Equity Research

J&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook for 2023 is above expectations while sales fall short.

Johnson & Johnson (JNJ) Q4 Earnings Top Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 5.86% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRW

Mark Vickery headshot

Markets Stay Positive on Perceived Fed Slowing

by Mark Vickery

We're either letting the stern part of the narrative get past us or we're breathing some life into oversold indices. Perhaps a little of both.

Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance

by Zacks Equity Research

Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

Andrew Rocco headshot

Market on Tipping Point of New Bull Trend: These 5 Charts Illustrate Why

by Andrew Rocco

You never really know when a new bull trend has arrived for sure. However, by looking at different sides of the market you can begin to put the pieces of the puzzle together.

Discover Financial, Kimberly Clark, Johnson & Johnson and Synchrony Financial are part of Zacks Earnings Preview

by Zacks Equity Research

Discover Financial, Kimberly Clark, Johnson & Johnson and Synchrony Financial are highlights of Zacks Earnings Preview article.

Sheraz Mian headshot

Making Sense of the Early Q4 Results: Is An Earnings Cliff Coming?

by Sheraz Mian

By the end of this week, we will have seen quarterly results from about 28% of all S&P 500 members and will have a very good sense of whether the earnings-cliff narrative has started unfolding or been further pushed out.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's Donanemab Gets FDA's CRL, MRNA RSV Jab Study Succeeds

by Kinjel Shah

FDA gives CRL to Lilly's (LLY) Alzheimer's candidate, donanemab. Moderna's (MRNA) phase III study on its mRNA-based RSV vaccine candidate in older adults meets primary efficacy endpoints

J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector

by Zacks Equity Research

Growth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and Stelara. In the MedTech segment, continued recovery in worldwide procedure volume should drive sales.

Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VYM

J&J (JNJ) Discontinues HIV Vaccine Phase III Mosaico Study

by Zacks Equity Research

J&J (JNJ) discontinues phase III study on its investigational HIV vaccine regimen, which shows that the candidate lacks efficacy in preventing HIV.

Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VONV

Johnson & Johnson (JNJ) Stock Moves -1.51%: What You Should Know

by Zacks Equity Research

In the latest trading session, Johnson & Johnson (JNJ) closed at $169.76, marking a -1.51% move from the previous day.

Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for VOOV

Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DGRO